Introduction {#Sec1}
============

Almost one-third of adults in the USA are obese (body mass index \[BMI\] of 30 kg/m^2^ or greater) \[[@CR1]\]. Worldwide obesity has doubled since 1980 \[[@CR2]\], and more patients who are obese are undergoing bariatric surgery as a method for weight control. Patients with a BMI greater than 40 kg/m^2^ or a BMI between 35 kg/m^2^ and 40 kg/m^2^ with co-morbid conditions are potential candidates for bariatric surgery. In addition, obesity is associated with other co-morbid chronic medical conditions such as orthopedic, cardiac, and pulmonary disease that make these patients more challenging to manage postoperatively. In these obese patients especially, successful postoperative pain management is critical with dual goals of reducing or eliminating pain and regaining mobility as quickly as possible \[[@CR3]\]. Opioids continue to be the mainstay of most postoperative multimodal therapy. However, appropriate concern about adverse events such as respiratory depression or oversedation in patients with obesity and challenges with venous access may lead to undertreatment of pain.

Fentanyl iontophoretic transdermal system (ITS) (IONSYS^®^, The Medicines Company, Parsippany, New Jersey) is a pre-programmed, needle-free drug delivery system used to deliver patient-controlled analgesia (PCA) for acute postoperative pain in adult patients during hospitalization. Fentanyl is administered via iontophoresis which is a transdermal delivery of fentanyl through the skin via the application of a low-intensity electrical field \[[@CR4]\]. Fentanyl ITS delivers doses based on patient demand. Unlike traditional PCA, no venous access or intravenous (IV) lines are needed to apply or administer the fentanyl ITS system. Given the increasing number of obese patients as well as the increasing number of surgical procedures being performed in this population, it is important to evaluate the relative efficacy and safety of fentanyl ITS in the obese population. The existing phase 3 dataset provides an initial opportunity to explore these questions. The primary purpose of these analyses was to determine if there were any differences between patients with high BMI and lower BMIs in terms of efficacy or safety. A secondary outcome was to compare fentanyl ITS versus morphine IV PCA to evaluate if the efficacy profile was similar between the two treatments by BMI category.

Methods {#Sec2}
=======

Trials were included in these analyses if they studied the fentanyl iontophoretic transdermal system in prospective randomized controlled trials and also included BMI. A literature search resulted in five unique clinical trials that are included in these analyses \[[@CR5]--[@CR9]\]. One additional study was not included as BMI data was not available \[[@CR10]\]. The manufacturer provided details for this analysis on a 6th phase 3 trial that has not been published. This represents all of the phase 3/3B trials conducted utilizing fentanyl ITS. The details of each trial are presented in Table [1](#Tab1){ref-type="table"}.Table 1Key study details for phase 3 and 3B clinical trials with fentanyl ITS (treated population)Study no.Surgical proceduresTest product(s); dosage regimen; route of administrationAll patients, *N*Duration of studyPrimary efficacy outcomeRandomized, double-blind, placebo-controlled trials C-95-016Abdominal\
OrthopedicA. Fentanyl ITS 40 µg up to 6 doses/h77Up to 24 hFentanyl ITS superior to placebo ITS (\# of pts who withdrew as a result of inadequate pain control \>3 h after application of study treatment)B. Placebo ITS25 Chelly et al. \[[@CR5]\]Abdominal\
Orthopedic\
ThoracicA. Fentanyl ITS 40 µg up to 6 doses/h154Up to 24 hFentanyl ITS superior to placebo ITS (% of pts withdrawn as a result of inadequate pain control after completing at least \>3 h of study treatment)B. Placebo ITS51 Viscusi et al. \[[@CR6]\]Abdominal\
Orthopedic\
Thoracic\
OtherA. Fentanyl ITS 40 µg up to 6 doses/h244Up to 24 hFentanyl ITS superior to placebo ITS (% of pts withdrawn as a result of inadequate pain control after completing at least \>3 h of study treatment)B. Placebo ITS240Randomized, open-label, active-comparator trials Viscusi et al. \[[@CR7]\]Abdominal\
Orthopedic\
Thoracic\
OtherA. Fentanyl ITS 40 µg up to 6 doses/h316Up to 72 hFentanyl ITS equivalent to morphine IV PCA (patient global assessment of the method of pain control during the first 24 h)B. Morphine IV PCA (1 mg/dose) up to 10 doses/h320 Hartrick et al. \[[@CR8]\]OrthopedicA. Fentanyl ITS 40 µg up to 6 doses/h395Up to 72 hFentanyl ITS equivalent to morphine IV PCA (patient global assessment ratings of the method of pain control of either "excellent" or "good" in the first 24 h)B. Morphine IV PCA (1 mg/dose) up to 10 doses/h404 Minkowitz et al. \[[@CR9]\]Abdominal\
PelvicA. Fentanyl ITS 40 µg up to 6 doses/h252Up to 72 hFentanyl ITS equivalent to morphine IV PCA (patient global assessment ratings of the method of pain control of either "excellent" or "good" in the first 24 h)B. Morphine IV PCA (1 mg/dose) up to 10 doses/h254*h* hours, *ITS* iontophoretic transdermal system, *IV PCA* intravenous patient-controlled analgesia

In all studies, patients admitted to the postanesthesia care unit after major surgery were titrated to comfort with opioids prior to receiving study drug. All studies utilized the validated patient global assessment of the method of pain control (PGA) \[[@CR11]\]. The PGA is a categorical 4-point scale (excellent, good, fair, or poor) with treatment success defined as excellent or good. The PGA was the primary outcome of the four active-comparator phase 3B trials. The PGA is rated by the patient directly and does not reflect the treating clinician or investigator's assessment. While the PGA was not designed as a patient-reported outcome instrument, it is a patient-reported instrument to assess the method of pain control. In the validation paper the authors concluded that "The PGA of the method of pain control is an informative and useful measure for assessing pain control provided by different drug delivery systems for patients experiencing postoperative pain." The studies also utilized the investigator global assessment of the method of pain control (IGA). The IGA is a similar categorical 4-point scale to the PGA with treatment success defined as excellent or good. Safety was assessed via treatment-emergent adverse events (TEAEs). For purposes of these analyses, the following subgroups were utilized: \<35 kg/m^2^, 35--40 kg/m^2^, and \>40 kg/m^2^. These group definitions were selected on the basis of indication prerequisites for bariatric surgery which currently includes a BMI of at least 40 kg/m^2^ or a BMI of 35 kg/m^2^ or more with a serious health problem linked to obesity \[[@CR12]\]. Five of the six studies have been previously published with full methodology \[[@CR5]--[@CR9]\]. The sixth study was a placebo-controlled trial similar in design to the other two placebo-controlled trials. The primary purpose of these analyses was to determine if there were any differences between patients with high BMI and lower BMIs in terms of efficacy or safety. A secondary purpose was to evaluate if there were any differences between patients treated with fentanyl ITS versus morphine IV PCA across the BMI categories.

Compliance with Ethics Guidelines {#Sec3}
---------------------------------

All studies received applicable institutional review board approval prior to initiation. All patients who had participated in the studies provided written informed consent prior to study enrollment. All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki, as revised in 2013.

Statistical Analysis {#Sec4}
--------------------

The evaluable efficacy population included patients who had at least 3 h of study treatment, consistent with the analyses for the original phase 3 trials. The safety population included all patients who received any study treatment, also referred to as the treated population.

Descriptive statistics were utilized for most variables, including the analysis of PGA, IGA, and safety. A meta-analysis was conducted on the secondary outcomes comparing fentanyl ITS with morphine IV PCA for the PGA and IGA and was performed according to the Cochrane methodology \[[@CR13]\]. The meta-analysis was conducted using random effects models \[[@CR13]\], with fixed effect models being explored as secondary analyses. For dichotomous variables, odds ratios (ORs) indicating the probability of the outcome occurring were calculated. Statistical tests were performed at the 0.05 significance level, with no multiplicity adjustments. Ninety-five percent confidence intervals (CIs) were provided for all parameters.

Only patients with observations at the given time points were included in the calculations. Any missing values were excluded from analyses.

Results {#Sec5}
=======

In the controlled studies included in these analyses there were a total of 1436 patients randomized to fentanyl ITS. There were 1212 who had BMIs \<35 kg/m^2^, 138 who had a BMI ≥35 kg/m^2^ and ≤40 kg/m^2^, and 86 who had a BMI \>40 kg/m^2^. In the placebo-controlled trials there were 316 patients randomized to placebo. Of these, there were 271 who had BMIs \<35 kg/m^2^, 30 who had a BMI \>35 kg/m^2^ and ≤40 kg/m^2^, and 15 who had a BMI \>40 kg/m^2^. In the active-comparator trials there were 977 patients randomized to morphine IV PCA. Of these, there were 802 who had BMIs \<35 kg/m^2^, 112 who had a BMI \>35 kg/m^2^ and ≤40 kg/m^2^, and 63 who had a BMI \>40 kg/m^2^. The demographic and baseline characteristics across the BMI categories for fentanyl ITS, morphine IV PCA, and placebo are presented in Table [2](#Tab2){ref-type="table"}. The majority of patients were female and white. The groups were similar across all treatments and BMI categories; however, there were fewer patients in the \>40 kg/m^2^ group who underwent orthopedic surgery compared to the other two BMI categories.Table 2Patient baseline demographics and characteristics (treated population)Fentanyl ITS\
BMI groupMorphine IV PCA\
BMI groupPlacebo\
BMI group\<35 kg/m^2^\
*N* = 121235--40 kg/m^2^\
*N* = 138\>40 kg/m^2^\
*N* = 86\<35 kg/m^2^\
*N* = 80235--40 kg/m^2^\
*N* = 112\>40 kg/m^2^\
*N* = 63\<35 kg/m^2^\
*N* = 27135--40 kg/m^2^\
*N* = 30\>40 kg/m^2^\
*N* = 15Age, years\
Mean (SD)55.1 (15.1)52.9 (13.7)47.6 (13.1)56.6 (15.2)50.7 (12.5)50.6 (12.1)52.3 (14.5)52.6 (15.0)47.5 (14.5)Sex, *n* (%) Female811 (66.9)100 (72.5)76 (88.4)528 (65.8)84 (75.0)47 (74.6)194 (71.6)19 (63.3)14 (93.3) Male401 (33.1)38 (27.5)10 (11.6)274 (34.2)28 (25.0)16 (25.4)77 (28.4)11 (36.7)1 (6.7)Race, *n* (%) Caucasian1001 (82.6)110 (79.7)62 (72.1)666 (83.0)80 (71.4)46 (73.0)235 (86.7)24 (80.0)12 (80.0) Black131 (10.8)18 (13.0)18 (20.9)93 (11.6)26 (23.2)13 (20.6)18 (6.6)3 (10.0)1 (6.7) Hispanic50 (4.1)5 (3.6)4 (4.7)30 (3.7)5 (4.5)3 (4.8)9 (3.3)3 (10.0)2 (13.3) Asian14 (1.2)005 (0.6)002 (0.7)00 Other16 (1.3)5 (3.6)2 (2.3)8 (1.0)1 (0.9)1 (1.6)7 (2.6)00Surgery type Orthopedic590 (48.7)71 (51.4)33 (38.4)444 (55.4)43 (38.4)27 (42.9)117 (43.2)14 (46.7)5 (33.3) Lower abdominal561 (46.3)62 (44.9)41 (47.7)327 (40.8)65 (58.0)27 (42.9)136 (50.2)14 (46.7)8 (53.3) Upper abdominal37 (3.1)4 (2.9)11 (12.8)21 (2.6)3 (2.7)7 (11.1)9 (3.3)1 (3.3)1 (6.7) Thoracic/chest13 (1.1)01 (1.2)4 (0.5)006 (2.2)01 (6.7) Other11 (0.9)1 (0.7)06 (0.7)1 (0.9)2 (3.2)3 (1.1)1 (3.3)0*BMI* body mass index, *ITS* iontophoretic transdermal system, *IV PCA* intravenous patient-controlled analgesia

The mean number of fentanyl ITS doses used in the first 24 h across the BMI categories was 32 doses in patients with BMI \<35 kg/m^2^, 30 doses in patients with BMI ≥35 kg/m^2^ and ≤40 kg/m^2^, and 32 doses in patients with BMI \>40 kg/m^2^. The mean number of doses of morphine IV PCA used in the first 24 h across the BMI categories was 39 doses in patients with BMI \<35 kg/m^2^, 46 doses in patients with BMI ≥35 kg/m^2^ and ≤40 kg/m^2^, and 40 doses in patients with BMI \>40 kg/m^2^. The mean number of doses of placebo ITS used in the first 24 h across the BMI categories was 24 doses in patients with BMI \<35 kg/m^2^, 19 doses in patients with BMI ≥35 kg/m^2^ and ≤40 kg/m^2^, and 30 doses in patients with BMI \>40 kg/m^2^.

The magnitude of treatment "success" on the PGA at 24 h was similar in the high BMI groups and the low BMI group in patients treated with fentanyl ITS (\<35 kg/m^2^: 946/1180 \[80.2%\]; 35--40 kg/m^2^: 103/136 \[75.7%\]; and \>40 kg/m^2^: 65/85 \[76.5%\]) (Table [3](#Tab3){ref-type="table"}). Similarly, the magnitude of patients rating their method of treatment as "excellent" at 24 h on the PGA was consistent across the high and low BMI groups (Table [3](#Tab3){ref-type="table"}). The IGA results at study discharge were similar between BMI categories for either treatment "success" or rating of "excellent" (Table [3](#Tab3){ref-type="table"}).Table 3Global assessments by BMI category (evaluable population)Fentanyl ITS\
BMI groupBMI \<35 kg/m^2^\
*N* = 1180\
*n* (%)BMI 35--40 kg/m^2^\
*N* = 136\
*n* (%)BMI \>40 kg/m^2^\
*N* = 85\
*n* (%)Patient global assessment at 24 h Success946 (80.2)103 (75.7)65 (76.5) Excellent564 (47.8)57 (41.9)42 (49.4)Investigator global assessment at last assessment Success988 (83.7)106 (77.9)62 (72.9) Excellent691 (58.6)66 (48.5)50 (58.8)The patient global assessment of the method of pain control and the investigator global assessment of the method of pain control are categorical 4-point scales (excellent, good, fair, or poor) with treatment "success" defined as ratings of either excellent or good*BMI* body mass index, *ITS* iontophoretic transdermal system, *IV PCA* intravenous patient-controlled analgesia

Analyzing the active-comparator trials, the proportion of patients with treatment "success" or rated as "excellent" on the PGA was comparable between fentanyl ITS and morphine IV PCA for the high and low BMI categories (Fig. [1](#Fig1){ref-type="fig"}a, b). Similarly, treatment "success" or ratings of "excellent" according to the IGA was comparable between fentanyl ITS and morphine IV PCA across high and low BMI categories (Fig. [1](#Fig1){ref-type="fig"}c, d).Fig. 1Patient global assessment of **a** success and **b** rating of excellent at 24 h. Investigator global assessment of **c** success and **d** rating of excellent at last assessment. *BMI* body mass index, *CI* confidence interval, *ITS* iontophoretic transdermal system*, IV PCA* intravenous patient-controlled analgesia, *OR* odds ratio. There are no statistically significant differences in either the PGA or the IGA between fentanyl ITS and morphine IV PCA when compared by BMI group. The patient global assessment of the method of pain control and the investigator global assessment of the method of pain control are categorical 4-point scales (excellent, good, fair, or poor) with treatment "success" defined as ratings of either excellent or good

The most common TEAEs were nausea, pyrexia, vomiting, headache, and application site erythema across all of the BMI categories in the patients randomized and treated with fentanyl ITS (Table [4](#Tab4){ref-type="table"}). There were a similar number of patients in the morphine IV PCA group who experienced these same AEs; however, pyrexia was seen in more morphine IV PCA patients than in fentanyl ITS patients and application site erythema was unique to fentanyl ITS.Table 4Treatment-emergent adverse events (\>2% in any BMI group) (safety population)Fentanyl ITS\
BMI groupMorphine IV PCA\
BMI groupPlacebo\
BMI group\<35 kg/m^2^\
*N* = 1212\
*n* (%)35--40 kg/m^2^\
*N* = 138\
*n* (%)\>40 kg/m^2^\
*N* = 86\
*n* (%)\<35 kg/m^2^\
*N* = 802\
*n* (%)35--40 kg/m^2^\
*N* = 112\
*n* (%)\>40 kg/m^2^\
*N* = 63\
*n* (%)\<35 kg/m^2^\
*N* = 271\
*n* (%)35--40 kg/m^2^\
*N* = 30\
*n* (%)\>40 kg/m^2^\
*N* = 15\
*n* (%)Nausea485 (40.0)53 (38.4)27 (31.4)364 (45.4)43 (38.4)18 (28.6)60 (22.1)7 (23.3)2 (13.3)Pyrexia222 (18.3)25 (18.1)19 (22.1)166 (20.7)28 (25.0)18 (28.6)26 (9.6)5 (16.7)2 (13.3)Vomiting151 (12.5)12 (8.7)7 (8.1)95 (11.8)13 (11.6)5 (7.9)18 (6.6)1 (3.3)3 (20.0)Headache118 (9.7)16 (11.6)14 (16.3)60 (7.5)8 (7.1)3 (4.8)19 (7.0)2 (6.7)0Application site erythema100 (8.3)17 (12.3)5 (5.8)0006 (2.2)1 (3.3)0Pruritus80 (6.6)6 (4.3)4 (4.7)88 (11.0)15 (13.4)6 (9.5)1 (0.4)00Anaemia78 (6.4)7 (5.1)4 (4.7)71 (8.9)6 (5.4)2 (3.2)1 (0.4)1 (3.3)0Dizziness58 (4.8)4 (2.9)1 (1.2)36 (4.5)3 (2.7)3 (4.8)4 (1.5)00Insomnia44 (3.6)6 (4.3)4 (4.7)25 (3.1)4 (3.6)3 (4.8)12 (4.4)1 (3.3)3 (20.0)Hypotension40 (3.3)8 (5.8)4 (4.7)51 (6.4)8 (7.1)2 (3.2)2 (0.7)00Constipation40 (3.3)3 (2.2)022 (2.7)3 (2.7)3 (4.8)2 (0.7)00Hypoxia40 (3.3)3 (2.2)1 (1.2)37 (4.6)9 (8.0)1 (1.6)1 (0.4)00Abdominal pain26 (2.1)1 (0.7)2 (2.3)14 (1.7)2 (1.8)1 (1.6)5 (1.8)00Urinary retention25 (2.1)4 (2.9)2 (2.3)24 (3.0)6 (5.4)1 (1.6)2 (0.7)00Application site pruritus24 (2.0)6 (4.3)2 (2.3)0001 (0.4)1 (3.3)0Anxiety22 (1.8)3 (2.2)014 (1.7)3 (2.7)2 (3.2)4 (1.5)1 (3.3)0Hypertonia20 (1.7)5 (3.6)2 (2.3)11 (1.4)1 (0.9)2 (3.2)1 (0.4)00Application site vesicles20 (1.7)3 (2.2)00002 (0.7)00Flatulence20 (1.7)2 (1.4)2 (2.3)9 (1.1)2 (1.8)3 (4.8)2 (0.7)00Back pain19 (1.6)3 (2.2)3 (3.5)11 (1.4)1 (0.9)1 (1.6)9 (3.3)1 (3.3)0Hypertension19 (1.6)2 (1.4)3 (3.5)11 (1.4)2 (1.8)04 (1.5)00Tachycardia18 (1.5)4 (2.9)1 (1.2)22 (2.7)10 (8.9)3 (4.8)1 (0.4)00Dyspepsia17 (1.4)2 (1.4)3 (3.5)9 (1.1)1 (0.9)1 (1.6)1 (0.4)00Application site reaction16 (1.3)3 (2.2)0000000Ileus15 (1.2)2 (1.4)2 (2.3)4 (0.5)3 (2.7)1 (1.6)1 (0.4)00Dyspnea9 (0.7)1 (0.7)2 (2.3)4 (0.5)01 (1.6)1 (0.4)00Paraesthesia8 (0.7)2 (1.4)2 (2.3)7 (0.9)1 (0.9)01 (0.4)00Somnolence18 (1.5)0017 (2.1)1 (0.9)2 (3.2)000Pharyngitis17 (1.4)0016 (2.0)4 (3.6)2 (3.2)5 (1.8)00Edema peripheral4 (0.3)1 (0.7)1 (1.2)11 (1.4)2 (1.8)3 (4.8)3 (1.1)00Pain in extremity15 (1.2)2 (1.4)1 (1.2)9 (1.1)02 (3.2)1 (0.4)00Injection site reaction10 (0.8)2 (1.4)08 (1.0)1 (0.9)3 (4.8)000Oliguria4 (0.3)1 (0.7)1 (1.2)7 (0.9)2 (1.8)3 (4.8)000Cough3 (0.2)01 (1.2)3 (0.4)02 (3.2)2 (0.7)00Osteoarthritis1 (0.1)001 (0.1)02 (3.2)000Pain11 (0.9)03 (3.5)7 (0.9)001 (0.4)01 (6.7)Application site oedema3 (0.2)02 (2.3)000000Oedema Peripheral4 (0.3)1 (0.7)1 (1.2)11 (1.4)1 (0.9)2 (3.2)3 (1.1)00Thrombosis000002 (3.2)000Hypokalemia15 (1.2)(0.7)04 (0.5)1 (0.9)2 (3.2)1 (0.4)00*BMI* body mass index, *ITS* iontophoretic transdermal system, *IV PCA* intravenous patient-controlled analgesia

Discussion {#Sec6}
==========

In the controlled studies included in these analyses there were 1436 patients who were treated with fentanyl ITS. These phase 3 studies were designed to be inclusive of a broad range of weights, with no maximum BMI specified in the inclusion/exclusion criteria. The distribution of patients across BMIs was expectedly not even, reflective of the surgical population; however, there were a sizeable number of patients in the higher BMI categories (138 with a BMI ≥35 kg/m^2^ and ≤40 kg/m^2^, and 86 with a BMI \>40 kg/m^2^). Overall, treatment success, as assessed with the PGA of the method of pain control, with fentanyl ITS was 76.5% in the highest BMI group (\>40 kg/m^2^) group, which was consistent with the results in the lower BMI categories. Similar results were seen with the IGA. Therefore, it appears that fentanyl ITS is equally effective in the high and low BMI categories. The comparison of fentanyl ITS to morphine IV PCA by each BMI category showed overall consistency between the two treatments as assessed using either the PGA or IGA, further supporting efficacy in high BMI patients.

Fentanyl and morphine are powerful opioids; therefore, it is expected that the pain control is similar between these two modalities (fentanyl ITS and morphine IV PCA). However, the additional benefits of fentanyl ITS relating to the validated instruments of physical therapy ease-of-care \[[@CR14]\], nurse ease-of-care \[[@CR15]\], and patient ease-of-care \[[@CR16]\] have been evaluated and published in other analyses of the full phase 3 dataset. In addition, postoperative mobility is important for every patient undergoing surgery and especially so for obese patients. Early patient mobilization has been shown to reduce the cost of care and improve patient outcomes, whereas immobility is associated with increased complications, length of stays, and costs \[[@CR17]--[@CR19]\]. Fentanyl ITS is an effective analgesic in the postoperative period and also does not require an IV line and associated equipment (pumps, IV poles). Fentanyl ITS has demonstrated in a double-blind clinical trial that patients find it easier to mobilize when compared to morphine IV PCA \[[@CR20]\]. A previous analysis evaluated mobility with fentanyl ITS and morphine IV PCA and found that patients treated with fentanyl ITS were better able to mobilize in the postoperative period than those treated with morphine IV PCA across high and low BMI ranges that were assessed: \<25 kg/m^2^; 25 kg/m^2^ to \<30 kg/m^2^; 30 kg/m^2^ to \<40 kg/m^2^; and \>40 kg/m^2^ \[[@CR21]\].

Intravenous access can be challenging to obtain and maintain in obese patients \[[@CR22]\]. Notably, patients with poor venous access may experience interruption of standard IV PCA. One of the features of fentanyl ITS is that it reduces the need for a separate IV line for PCA administration in patients and therefore can be advantageous to utilize in the obese patient population.

The mean number of doses of fentanyl ITS utilized in the first 24 h did not differ between the BMI categories. One research group has previously shown that the G allele of the*OPRM1* gene encoding the mu receptor is more common in patients who are obese \[[@CR23]\]. This polymorphism has been associated with an increase in the requirement for morphine and fentanyl for pain relief. However, this was not evident in these analyses. Neither fentanyl ITS nor morphine IV PCA showed differences in doses used between the BMI categories. However, it is informative to note that as with other PCA systems, the fentanyl ITS system allows the patient to individualize their pain management regimen; therefore, patients requiring more fentanyl may take up to 80 doses in a 24-h period and those requiring less can take less.

Overall, the safety profile was generally similar across the high and low BMI categories. The TEAEs observed most often in the fentanyl ITS group and morphine IV PCA group are common to all opioids and include nausea, pyrexia, vomiting, and headache. Nausea, vomiting, and dizziness were all slightly less common in the BMI \>40 kg/m^2^ group compared to the BMI \<35 kg/m^2^ group, while headache was slightly more common in the \>40 kg/m^2^ group compared to the BMI \<35 kg/m^2^ and the 35--40 kg/m^2^ groups.

Respiratory depression is of particular importance in an obese population and needs to be carefully evaluated and monitored when using opioids. In this analysis, in the fentanyl ITS groups, hypoxia was reported in 3.3% of patients with a BMI \<35 kg/m^2^, in 2.2% of patients with a BMI ≥35 kg/m^2^ to ≤40 kg/m^2^, and in 1.2% of patients with a BMI \>40 kg/m^2^. In a meta-analysis that was performed using the active-comparator trials, opioid-related adverse events (including respiratory depression and sedation) were assessed in the aggregate study population \[[@CR24]\]. During the development program with more than 2500 patients treated with fentanyl ITS, there were no patients treated with fentanyl ITS who experienced clinically relevant respiratory depression (CRRD), and there were five patients in the morphine IV PCA group who did experience CRRD \[[@CR25]\]. However, despite the low rates of CRRD in the clinical studies, it is still important to closely monitor patients being treated with any opioid, including fentanyl ITS, for signs of sedation and respiratory depression. This is especially true for patients who are obese and may be more predisposed to these adverse events.

One limitation of these analyses is that none of the studies were designed to specifically look at BMI and therefore the population is not evenly distributed between the categories. However, this is a reasonably large sample of patients who are obese or morbidly obese. Another limitation is the selection of the BMI categories. These categories were chosen for their clinical relevance to reflect the categories that are commonly used to assess for bariatric surgery eligibility \[[@CR12]\]; however, it is reassuring that there was a great deal of consistency across the BMI categories in terms of safety and efficacy. The main purpose of these analyses was to evaluate the safety and efficacy of fentanyl ITS in the high and low BMI categories; however, we also compared the efficacy and safety to morphine IV PCA as there were fairly large sample sizes available from the clinical trial database. Another limitation of these studies, and therefore these analyses, is that they do not factor in multimodal analgesia treatment. It is important to remember that the primary purpose of the studies included was to evaluate the safety and efficacy of fentanyl ITS for regulatory submissions and ultimately drug approval and therefore multimodal analgesia was not included in the methodology. There were some additional endpoints that would have been useful to have measured, such as time to first bowel movement, time to getting up from bed etc.; however, these were not included in the design of the trials and therefore there is no information contained to specifically address these issues within the database. Further research in patients with high BMI using fentanyl ITS in multimodal treatment would be useful to confirm and extend the findings of this paper.

Conclusion {#Sec7}
==========

In these analyses, fentanyl ITS was as efficacious, as assessed by the PGA for pain control treatment "success", in patients with high BMI (\>40 kg/m^2^) as it was for those with lower BMIs (\<35 kg/m^2^ or 35--40 kg/m^2^) and was generally well tolerated across all BMI categories. Therefore, the results suggest that fentanyl ITS is a valuable option for the short-term treatment of postoperative pain in patients of all BMIs including the obese and morbidly obese.
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